PATENT CLAIM ANALYSIS

Application Number: 16200334
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-03
Patent Classification: ["424", "423000"]

Abstract:
Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.

Claim (Index 3):
The hydrogel capsules of  claim 1  or  2 , wherein the core layer comprises a therapeutic, prophylactic, or diagnostic agent.

Metadata:
- Claim Count in Document: 59.0
- Percentile: 98.0
- Lexical Diversity: 1.58333
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14776639', '13831250', '13400382', '15831570', '15317657']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8064181979766588
- 35 USC 102 Novelty (BERT): 0.6125397434770995
- Combined Prediction Score: 0.787030352526703
- Mean Citation Score: 458.67156000000006
- Max Citation Score: 582.405
- Similarity Product: 492.5220456531644

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test